William A. Erhardt

Oligomerix, Inc

$4,567,070

Attributed

$4,567,070

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.3M · FY2022–24

$2.5M$1.9M$1.3M$625K$0

'22

'23

'24

Funding mix

By agency

NIH$4,567,070 · 1

By mechanism

R01$4,567,070 · 1

Top collaborators

No co-investigators on record.

Most similar at Oligomerix, Inc

Same institution · by research overlap

James G. Moe$22,112,369

Others in their field

Other Rising Stars on “Alzheimer&Apos”

Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
Yanling Wang · Rush University Medical Center$2,986,919
William G Mantyh · University Of Minnesota$2,961,521
Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
Noah Ray Johnson · University Of Colorado Denver$2,282,487

Research focus

Alzheimer&AposIn Vitro AssayCanis FamiliarisFormulationInhibitorIncidenceCost EffectiveDrug DevelopmentAdverse EventFirst-In-HumanDoseHealthy VolunteerAmericanHuman StudyDrug KineticsCohortCostCaregiversCause Of DeathClinical DevelopmentClinical ResearchElderlyIn VitroIn Vivo Evaluation

Grant awards (4)

First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers$336,857

R01 · FY2024 · AG · contact PI

First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers$2,039,616

R01 · FY2023 · AG · contact PI

First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers$272,708

R01 · FY2023 · AG · contact PI

First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers$1,917,889

R01 · FY2022 · AG · contact PI